Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

90.0%

+3.5% vs industry average

Late-Stage Pipeline

45%

5 trials in Phase 3/4

Results Transparency

100%

9 of 9 completed trials have results

Key Signals

9 with results

Enrollment Performance

Analytics

Phase 2

5(45.5%)

Phase 3

3(27.3%)

Phase 4

2(18.2%)

N/A

1(9.1%)

11Total

Phase 2(5)

Phase 3(3)

Phase 4(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT01798589Phase 4Completed

Bioequivalence of Ethylenediamine Dihydrochloride Study

Role: lead

NCT02028182Phase 2Completed

Clinical Evaluation of Lyral® Dose Response Study

Role: lead

NCT04500834Phase 3Unknown

Metal Panel Allergen Patch Test Study

Role: lead

NCT02615249Phase 2Completed

Clinical Evaluation of Metal Panel Allergens: Dose Response Study

Role: lead

NCT02028208Phase 2Completed

Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study

Role: lead

NCT01797562Not ApplicableCompleted

Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents

Role: lead

NCT00795951Phase 4Completed

Clinical Evaluation of T.R.U.E. TEST in Children and Adolescents

Role: lead

NCT00640614Phase 3Completed

Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy

Role: lead

NCT00612768Phase 2Completed

Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations

Role: lead

NCT00640250Phase 2Completed

Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response

Role: lead

NCT01518348Phase 3Withdrawn

Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents

Role: lead

All 11 trials loaded